Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc., with its ticker symbol MODD, is a company operating in the medical device industry, specializing in the design, development, and commercialization of innovative insulin pumps. The company's main business activities revolve around modernizing technology to increase pump adoption in the diabetes marketplace. Modular Medical operates in the diabetes market, providing insulin pumps to individuals with type 1 and type 2 diabetes who require insulin therapy.

Modular Medical generates revenue primarily from its insulin pump sales, with its primary product being the MODD1 pump. The MODD1 pump is a high-precision pump designed to be the best choice for new pump patients due to its ease of use, affordability, and revolutionary design and internal technology that enable precision with low-cost manufacture and high reproducibility. The pump has a simple button interface, easy to learn and use, and a slim profile, making it an attractive option for diabetes patients. The pump's innovative design features a two-part patch pump, with a reusable and a disposable component, which snap together to form the working system. This design allows for a 90-day reusable and a 3-day disposable cartridge, making it easier for patients to manage their insulin therapy.

Modular Medical's position within the industry is unique due to its innovative technology and focus on simplicity, affordability, and ease of use. The company's primary competitors are Medtronic, Tandem, and Insulet, which offer more complex and expensive insulin pumps. Modular Medical believes that its MODD1 pump will appeal to the "Almost Pumpers" segment, which has been underserved by current pump offerings. The company's market research suggests that the insulin pump market is at an inflection point, with a growing demand for simpler, more affordable, and easier-to-use insulin pumps. The COVID-19 pandemic has accelerated this trend, with patients and healthcare providers seeking more convenient and remote care options. Modular Medical believes that its MODD1 pump is well-positioned to capitalize on this trend and become the leader in expanding access to insulin pump technology to a wider portion of the diabetes population.

Modular Medical's future product roadmap includes the development of MODD1+, which will add phone-based control and Alternative Controller Enabled (ACE) and Automated Insulin Delivery (AID) capability to allow integration with popular continuous glucose monitors. The company also plans to develop MODD2, a full-featured, multi-chamber pump optimized for high time-in-range fully autonomous close loop insulin delivery.